1. White KP, Speechley M, Harth M, Ostbye T: The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario. J Rheumatol 1999;26:1570-1576.
3. Häuser W, Sarzi-Puttini P, Fitzcharles MA: Fibromyalgia syndrome: under-, over- and misdiagnosis. Clin Exp Rheumatol 2019;37 Suppl 116:90-97.
8. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al: 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319-329.
9. Arnold LM, Hudson JI, Hess EV, Ware AE, Fritz DA, Auchenbach MB, et al: Family study of fibromyalgia. Arthritis Rheum 2004;50:944-952.
11. Jones KD, Gelbart T, Whisenant TC, Waalen J, Mondala TS, Iklé DN, et al: Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia. Clin Exp Rheumatol 2016;34(2 Suppl 96):S89-S98.
13. Mogil JS: Pain genetics: past, present and future. Trends Genet 2012;28:258-266.
16. Limer KL, Nicholl BI, Thomson W, McBeth J: Exploring the genetic susceptibility of chronic widespread pain: the tender points in genetic association studies. Rheumatology (Oxford) 2008;47:572-577.
17. Graeff FG: Serotonergic systems. Psychiatr Clin North Am 1997;20:723-739.
18. Roth BL: Multiple serotonin receptors: clinical and experimental aspects. Ann Clin Psychiatry 1994;6:67-78.
19. Roth BL, Xia Z: Molecular and cellular mechanisms for the polarized sorting of serotonin receptors: relevance for genesis and treatment of psychosis. Crit Rev Neurobiol 2004;16:229-236.
20. Mergener M, Becker RM, dos Santos AF, dos Santos GA, de Andrade FM: Influence of the interaction between environmental quality and T102C SNP in the HTR2A gene on fibromyalgia susceptibility. Rev Bras Reumatol 2011;51:594-602.
22. Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Krüger M, Schoeps P, et al: Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42:2482-2488.
23. Oswald LM, McCaul M, Choi L, Yang X, Wand GS: Catechol-O-methyltransferase polymorphism alters hypothalamic-pituitary-adrenal axis responses to naloxone: a preliminary report. Biol Psychiatry 2004;55:102-105.
24. Drabant EM, Hariri AR, Meyer-Lindenberg A, Munoz KE, Mattay VS, Kolachana BS, et al: Catechol O-methyltransferase val158met genotype and neural mechanisms related to affective arousal and regulation. Arch Gen Psychiatry 2006;63:1396-1406.
26. Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, et al: Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet 2005;14:135-143.
27. Martínez-Jauand M, Sitges C, Rodríguez V, Picornell A, Ramon M, Buskila D, et al: Pain sensitivity in fibromyalgia is associated with catechol-O-methyltransferase (COMT) gene. Eur J Pain 2013;17:16-27.
28. Inanir A, Karakus N, Ates O, Sezer S, Bozkurt N, Inanir S, et al: Clinical symptoms in fibromyalgia are associated to catechol-O-methyltransferase (COMT) gene Val158Met polymorphism. Xenobiotica 2014;44:952-956.
31. Wood PB: Role of central dopamine in pain and analgesia. Expert Rev Neurother 2008;8:781-797.
32. Wood PB, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner EA, et al: Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007;25:3576-3582.
33. Buskila D, Cohen H, Neumann L, Ebstein RP: An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004;9:730-731.
34. Potvin S, Larouche A, Normand E, de Souza JB, Gaumond I, Grignon S, et al: DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J Pain 2009;10:969-975.
37. Kosek E, Martinsen S, Gerdle B, Mannerkorpi K, Löfgren M, Bileviciute-Ljungar I, et al: The translocator protein gene is associated with symptom severity and cerebral pain processing in fibromyalgia. Brain Behav Immun 2016;58:218-227.
38. Park DJ, Kim SH, Nah SS, Lee JH, Kim SK, Lee YA, et al: Polymorphisms of the TRPV2 and TRPV3 genes associated with fibromyalgia in a Korean population. Rheumatology (Oxford) 2016;55:1518-1527.
44. Ciampi de Andrade D, Maschietto M, Galhardoni R, Gouveia G, Chile T, Victorino Krepischi AC, et al: Epigenetics insights into chronic pain: DNA hypomethylation in fibromyalgia: a controlled pilot-study. Pain 2017;158:1473-1480.
46. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
52. Al-Allaf AW, Dunbar KL, Hallum NS, Nosratzadeh B, Templeton KD, Pullar T: A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. Rheumatology (Oxford) 2002;41:450-453.
53. Cruz BA, Catalan-Soares B, Proietti F: Higher prevalence of fibromyalgia in patients infected with human T cell lymphotropic virus type I. J Rheumatol 2006;33:2300-2303.
54. Demitrack MA, Crofford LJ: Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci 1998;840:684-697.
56. Suarez-Roca H, Silva JA, Arcaya JL, Quintero L, Maixner W, Pinerua-Shuhaibar L: Role of mu-opioid and NMDA receptors in the development and maintenance of repeated swim stress-induced thermal hyperalgesia. Behav Brain Res 2006;167:205-211.
60. Suarez-Roca H, Leal L, Silva JA, Pinerua-Shuhaibar L, Quintero L: Reduced GABA neurotransmission underlies hyperalgesia induced by repeated forced swimming stress. Behav Brain Res 2008;189:159-169.
63. Buskila D, Atzeni F, Sarzi-Puttini P: Etiology of fibromyalgia: the possible role of infection and vaccination. Autoimmun Rev 2008;8:41-43.
64. Hunskar GS, Rortveit G, Litleskare S, Eide GE, Hanevik K, Langeland N, et al: Prevalence of fibromyalgia 10 years after infection with Giardia lamblia: a controlled prospective cohort study. Scand J Pain 2021;22:348-355.
68. Buskila D, Neumann L, Vaisberg G, Alkalay D, Wolfe F: Increased rates of fibromyalgia following cervical spine injury: a controlled study of 161 cases of traumatic injury. Arthritis Rheum 1997;40:446-452.
70. Clauw DJ, Engel CC Jr, Aronowitz R, Jones E, Kipen HM, Kroenke K, et al: Unexplained symptoms after terrorism and war: an expert consensus statement. J Occup Environ Med 2003;45:1040-1048.
71. McBeth J, Macfarlane GJ, Benjamin S, Morris S, Silman AJ: The association between tender points, psychological distress, and adverse childhood experiences: a community-based study. Arthritis Rheum 1999;42:1397-1404.
72. Jones GT, Power C, Macfarlane GJ: Adverse events in childhood and chronic widespread pain in adult life: results from the 1958 British Birth Cohort Study. Pain 2009;143:92-96.
75. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA, et al: Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis Rheum 1994;37:1583-1592.
76. Qiao ZG, Vaerøy H, Mørkrid L: Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. J Rheumatol 1991;18:1383-1389.
77. Adler GK, Kinsley BT, Hurwitz S, Mossey CJ, Goldenberg DL: Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999;106:534-543.
78. Martínez-Lavín M, Hermosillo AG, Rosas M, Soto ME: Circadian studies of autonomic nervous balance in patients with fibromyalgia: a heart rate variability analysis. Arthritis Rheum 1998;41:1966-1971.
81. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F: The hypothalamo-pituitary-adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007;10:13-25.
82. Kuehl LK, Michaux GP, Richter S, Schächinger H, Anton F: Increased basal mechanical pain sensitivity but decreased perceptual wind-up in a human model of relative hypocortisolism. Pain 2010;149:539-546.
83. Michaux GP, Magerl W, Anton F, Treede RD: Experimental characterization of the effects of acute stresslike doses of hydrocortisone in human neurogenic hyperalgesia models. Pain 2012;153:420-428.
84. van Middendorp H, Lumley MA, Jacobs JW, Bijlsma JW, Geenen R: The effects of anger and sadness on clinical pain reports and experimentally-induced pain thresholds in women with and without fibromyalgia. Arthritis Care Res (Hoboken) 2010;62:1370-1376.
85. Griep EN, Boersma JW, de Kloet ER: Altered reactivity of the hypothalamic-pituitary-adrenal axis in the primary fibromyalgia syndrome. J Rheumatol 1993;20:469-474.
87. Dinan TG: Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci 1996;58:1683-1694.
88. McCain GA, Tilbe KS: Diurnal hormone variation in fibromyalgia syndrome: a comparison with rheumatoid arthritis. J Rheumatol Suppl 1989;19:154-157.
89. Crofford LJ, Young EA, Engleberg NC, Korszun A, Brucksch CB, McClure LA, et al: Basal circadian and pulsatile ACTH and cortisol secretion in patients with fibromyalgia and/or chronic fatigue syndrome. Brain Behav Immun 2004;18:314-325.
91. Wingenfeld K, Heim C, Schmidt I, Wagner D, Meinlschmidt G, Hellhammer DH: HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med 2008;70:65-72.
92. Crofford LJ: Neuroendocrine aspects of fibromyalgia. J Musculoskelet Pain 1994;2:125-133.
93. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM: Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997;24:1384-1389.
98. Moldofsky H, Scarisbrick P, England R, Smythe H: Musculosketal symptoms and non-REM sleep disturbance in patients with “fibrositis syndrome” and healthy subjects. Psychosom Med 1975;37:341-351.
99. Moldofsky H, Scarisbrick P: Induction of neurasthenic musculoskeletal pain syndrome by selective sleep stage deprivation. Psychosom Med 1976;38:35-44.
100. Mork PJ, Nilsen TI: Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum 2012;64:281-284.
101. Lentz MJ, Landis CA, Rothermel J, Shaver JL: Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. J Rheumatol 1999;26:1586-1592.
102. Nicassio PM, Moxham EG, Schuman CE, Gevirtz RN: The contribution of pain, reported sleep quality, and depressive symptoms to fatigue in fibromyalgia. Pain 2002;100:271-279.
104. Hamilton NA, Affleck G, Tennen H, Karlson C, Luxton D, Preacher KJ, et al: Fibromyalgia: the role of sleep in affect and in negative event reactivity and recovery. Health Psychol 2008;27:490-497.
105. Moldofsky H: The significance of dysfunctions of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am 2009;35:275-283.
107. Smith MT, Edwards RR, McCann UD, Haythornthwaite JA: The effects of sleep deprivation on pain inhibition and spontaneous pain in women. Sleep 2007;30:494-505.
108. Onen SH, Alloui A, Gross A, Eschallier A, Dubray C: The effects of total sleep deprivation, selective sleep interruption and sleep recovery on pain tolerance thresholds in healthy subjects. J Sleep Res 2001;10:35-42.
109. Roehrs T, Hyde M, Blaisdell B, Greenwald M, Roth T: Sleep loss and REM sleep loss are hyperalgesic. Sleep 2006;29:145-151.
110. Tononi G, Cirelli C: Sleep function and synaptic homeostasis. Sleep Med Rev 2006;10:49-62.
116. Andersen ML, Nascimento DC, Machado RB, Roizenblatt S, Moldofsky H, Tufik S: Sleep disturbance induced by substance P in mice. Behav Brain Res 2006;167:212-218.
118. Evengard B, Nilsson CG, Lindh G, Lindquist L, Eneroth P, Fredrikson S, et al: Chronic fatigue syndrome differs from fibromyalgia: no evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998;78:153-155.
120. Rizzi M, Radovanovic D, Santus P, Airoldi A, Frassanito F, Vanni S, et al: Influence of autonomic nervous system dysfunction in the genesis of sleep disorders in fibromyalgia patients. Clin Exp Rheumatol 2017;35 Suppl 105:74-80.
121. Boissevain MD, McCain GA: Toward an integrated understanding of fibromyalgia syndrome. II. Psychological and phenomenological aspects. Pain 1991;45:239-248.
122. Epstein SA, Kay G, Clauw D, Heaton R, Klein D, Krupp L, et al: Psychiatric disorders in patients with fibromyalgia: a multicenter investigation. Psychosomatics 1999;40:57-63.
124. Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ: The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005;52:1577-1584.
125. Cohen H, Buskila D, Neumann L, Ebstein RP: Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002;46:845-847.
127. Gold PW, Gabry KE, Yasuda MR, Chrousos GP: Divergent endocrine abnormalities in melancholic and atypical depression: clinical and pathophysiologic implications. Endocrinol Metab Clin North Am 2002;31:37-62.
129. Mendieta D, De la Cruz-Aguilera DL, Barrera-Villalpando MI, Becerril-Villanueva E, Arreola R, Hernández-Ferreira E, et al: IL-8 and IL-6 primarily mediate the inflammatory response in fibromyalgia patients. J Neuroimmunol 2016;290:22-25.
130. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH: Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology (Oxford) 2001;40:743-749.
131. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al: A meta-analysis of cytokines in major depression. Biol Psychiatry 2010;67:446-457.
133. Klein R, Berg PA: High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res 1995;1:21-26.
134. Werle E, Fischer HP, Müller A, Fiehn W, Eich W: Antibodies against serotonin have no diagnostic relevance in patients with fibromyalgia syndrome. J Rheumatol 2001;28:595-600.
139. Ranzolin A, Duarte AL, Bredemeier M, da Costa Neto CA, Ascoli BM, Wollenhaupt-Aguiar B, et al: Evaluation of cytokines, oxidative stress markers and brain-derived neurotrophic factor in patients with fibromyalgia: a controlled cross-sectional study. Cytokine 2016;84:25-28.
140. Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y: Fibromyalgia and cytokines. Immunol Lett 2014;161:200-203.
146. Kadetoff D, Lampa J, Westman M, Andersson M, Kosek E: Evidence of central inflammation in fibromyalgia-increased cerebrospinal fluid interleukin-8 levels. J Neuroimmunol 2012;242:33-38.
147. Puma C, Danik M, Quirion R, Ramon F, Williams S: The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem 2001;78:960-971.
150. Wallace DJ: Is there a role for cytokine based therapies in fibromyalgia. Curr Pharm Des 2006;12:17-22.
151. Pillemer SR, Bradley LA, Crofford LJ, Moldofsky H, Chrousos GP: The neuroscience and endocrinology of fibromyalgia. Arthritis Rheum 1997;40:1928-1939.
153. Vaerøy H, Helle R, Førre Ø, Kåss E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 1988;32:21-26.
154. Russell IJ, Orr MD, Littman B, Vipraio GA, Alboukrek D, Michalek JE, et al: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994;37:1593-1601.
155. Rossi SG, Dickerson IM, Rotundo RL: Localization of the calcitonin gene-related peptide receptor complex at the vertebrate neuromuscular junction and its role in regulating acetylcholinesterase expression. J Biol Chem 2003;278:24994-25000.
156. Maggi CA: Tachykinins and calcitonin gene-related peptide (CGRP) as co-transmitters released from peripheral endings of sensory nerves. Prog Neurobiol 1995;45:1-98.
161. Valdés M, Collado A, Bargalló N, Vázquez M, Rami L, Gómez E, et al: Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010;62:1829-1836.
162. Harris RE, Sundgren PC, Pang Y, Hsu M, Petrou M, Kim SH, et al: Dynamic levels of glutamate within the insula are associated with improvements in multiple pain domains in fibromyalgia. Arthritis Rheum 2008;58:903-907.
163. Giovengo SL, Russell IJ, Larson AA: Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999;26:1564-1569.
165. Juhl JH: Fibromyalgia and the serotonin pathway. Altern Med Rev 1998;3:367-375.
166. Potvin S, Grignon S, Marchand S: Human evidence of a supra-spinal modulating role of dopamine on pain perception. Synapse 2009;63:390-402.
172. Borg-Stein J: Management of peripheral pain generators in fibromyalgia. Rheum Dis Clin North Am 2002;28:305-317.
173. Clauw DJ: Fibromyalgia and related conditions. Mayo Clin Proc 2015;90:680-692.
174. Gerwin R: Are peripheral pain generators important in fibromyalgia and chronic widespread pain? Pain Med 2013;14:777-778.
175. Üçeyler N, Zeller D, Kahn AK, Kewenig S, Kittel-Schneider S, Schmid A, et al: Small fibre pathology in patients with fibromyalgia syndrome. Brain 2013;136(Pt 6):1857-1867.
177. Grayston R, Czanner G, Elhadd K, Goebel A, Frank B, Üçeyler N, et al: A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia: implications for a new paradigm in fibromyalgia etiopathogenesis. Semin Arthritis Rheum 2019;48:933-940.
178. Gerdle B, Forsgren MF, Bengtsson A, Leinhard OD, Sören B, Karlsson A, et al: Decreased muscle concentrations of ATP and PCR in the quadriceps muscle of fibromyalgia patients: a 31P-MRS study. Eur J Pain 2013;17:1205-1215.
179. Drewes AM, Andreasen A, Schrøder HD, Høgsaa B, Jennum P: Pathology of skeletal muscle in fibromyalgia: a histo-immuno-chemical and ultrastructural study. Br J Rheumatol 1993;32:479-483.
181. Bunimovich O, Grassi M, Baer MR: Systemic mastocytosis: classification, pathogenesis, diagnosis, and treatment. Cutis 2009;83:29-36.
183. Bengtsson M, Bengtsson A, Jorfeldt L: Diagnostic epidural opioid blockade in primary fibromyalgia at rest and during exercise. Pain 1989;39:171-180.
184. Staud R, Spaeth M: Psychophysical and neurochemical abnormalities of pain processing in fibromyalgia. CNS Spectr 2008;13(3 Suppl 5):12-17.
185. Nijs J, George SZ, Clauw DJ, Fernández-de-las-Peñas C, Kosek E, Ickmans K, et al: Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol 2021;3:e383-e392.
187. Desmeules JA, Cedraschi C, Rapiti E, Baumgartner E, Finckh A, Cohen P, et al: Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003;48:1420-1429.
188. McDermid AJ, Rollman GB, McCain GA: Generalized hypervigilance in fibromyalgia: evidence of perceptual amplification. Pain 1996;66:133-144.
189. Geisser ME, Glass JM, Rajcevska LD, Clauw DJ, Williams DA, Kileny PR, et al: A psychophysical study of auditory and pressure sensitivity in patients with fibromyalgia and healthy controls. J Pain 2008;9:417-422.
191. Larson AA, Giovengo SL, Russell JI, Michalek JE: Changes in the concentrations of amino acids in the cerebrospinal fluid that correlate with pain in patients with fibromyalgia: implications for nitric oxide pathways. Pain 2000;87:201-211.
192. Uta D, Tsuboshima K, Nishijo H, Mizumura K, Taguchi T: Neuronal sensitization and synaptic facilitation in the superficial dorsal horn of a rat reserpine-induced pain model. Neuroscience 2021;479:125-139.
193. Gracely RH, Geisser ME, Giesecke T, Grant MA, Petzke F, Williams DA, et al: Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004;127(Pt 4):835-843.
198. Burgmer M, Gaubitz M, Konrad C, Wrenger M, Hilgart S, Heuft G, et al: Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. Psychosom Med 2009;71:566-573.
199. Kim DJ, Lim M, Kim JS, Son KM, Kim HA, Chung CK: Altered white matter integrity in the corpus callosum in fibromyalgia patients identified by tract-based spatial statistical analysis. Arthritis Rheumatol 2014;66:3190-3199.
200. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino acids in primary fibromyalgia: a controlled study. J Rheumatol 1992;19:90-94.
201. Jensen KB, Kosek E, Petzke F, Carville S, Fransson P, Marcus H, et al: Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009;144:95-100.
202. Truini A, Tinelli E, Gerardi MC, Calistri V, Iannuccelli C, La Cesa S, et al: Abnormal resting state functional connectivity of the periaqueductal grey in patients with fibromyalgia. Clin Exp Rheumatol 2016;34(2 Suppl 96):S129-S133.
206. Staud R, Boissoneault J, Lai S, Mejia MS, Ramanlal R, Godfrey MM, et al: Spinal cord neural activity of patients with fibromyalgia and healthy controls during temporal summation of pain: an fMRI study. J Neurophysiol 2021;126:946-956.